Inaktiver Wert

Andere Sprachen ProMIS Neurosciences, Inc. Toronto S.E.

Aktien

A3DM9Q

CA74346M4065

PMN

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies	30.04.
ProMIS Neurosciences, Inc. Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies	30.04.
ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS	09.04.
ProMIS Neurosciences Inc. Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as A Treatment Target for ALS	09.04.
ProMIS Neurosciences to Present in Upcoming Investor Conferences in April	05.04.
ProMIS Neurosciences to Present in Upcoming Investor Conferences in April	04.04.
ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights	01.04.
ProMIS Neurosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01.04.
ProMIS Neurosciences : Corporate Overview	29.03.
ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio	11.03.
ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference	22.02.
ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine	22.01.
ProMIS Neurosciences Issues Letter to Shareholders	08.01.
ProMIS Neurosciences, Inc. Announces Management Changes	03.01.
ProMIS Neurosciences, Inc. Announces CEO Changes	03.01.
ProMIS Neurosciences, Inc. Announces Leadership Transition	03.01.
ProMIS Neurosciences Announces Publication on Novel Target for ALS	20.12.
ProMIS Neurosciences Announces Publication on Novel Target for ALS	20.12.
ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer’s Disease	20.11.
Promis Neurosciences Inc. Doses First Subjects in Phase 1A Clinical Trial of PMN310 to Treat Alzheimer's Disease	20.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen ProMIS Neurosciences, Inc. Toronto S.E.

Aktien

A3DM9Q

CA74346M4065

PMN

Andere Sprachen

Filter